Parse Biosciences Expands Global Access by Certifying Single Cell Discoveries as a Service Provider
30.9.2025 15:00:00 EEST | Business Wire | Press release
Parse Biosciences, the leader in scalable and accessible single cell sequencing, is pleased to welcome the Netherlands-based Single Cell Discoveries as the newest member of its Certified Service Provider (CSP) Program. As a certified provider, Single Cell Discoveries will expand access to Parse’s single cell technology, pairing it with a team uniquely dedicated to single cell science to support researchers across Europe and worldwide.
Introduced in 2024, the CSP Program connects researchers with rigorously vetted partners for outsourcing single cell projects of any size. By maintaining exacting standards for data quality, scalability, and service, the program helps labs accelerate discovery with confidence.
“Becoming the first service provider in Europe to join Parse’s Certified Service Provider program reflects our commitment to leadership in single cell science,” said Mauro Muraro, PhD, co-founder and CEO of Single Cell Discoveries. “Partnering with Parse’s scalable, fixation-friendly technology allows us to deliver high-quality results at the pace modern research demands, whether for a focused pilot or an atlas-scale study.”
“Expanding our CSP network ensures researchers have reliable, regional access to best-in-class single cell services,” said Alex Rosenberg, CEO and co-founder of Parse Biosciences. “With Single Cell Discoveries joining the program, scientists gain a trusted partner whose focus has always been single cell, now complemented by the scalability and precision that Parse enables.”
About Parse Biosciences
Parse Biosciences is a global life sciences company dedicated to accelerating advancements in human health and scientific research. By empowering researchers to conduct single cell sequencing with unparalleled scale and simplicity, Parse’s innovative solutions are driving breakthroughs in cancer treatment, tissue repair, stem cell therapy, and more. Built upon transformative technology developed at the University of Washington, Parse Biosciences has raised over $100 million and is used by over 3,000 labs worldwide. Its expanding product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and Trailmaker for advanced data analysis. Headquartered in Seattle’s vibrant South Lake Union district, Parse Biosciences recently inaugurated a 34,000-square-foot facility featuring state-of-the-art laboratories to support its mission of advancing global research. www.parsebiosciences.com
About Single Cell Discoveries
Single Cell Discoveries is a leading contract research organization (CRO) specializing in single-cell sequencing, spatial transcriptomics, and multiomic applications. Headquartered in Utrecht, the Netherlands, the company partners with biopharmaceutical organizations and academic institutions worldwide to accelerate drug discovery and innovation. With more than a decade of expertise, over 1,000 projects completed, and millions of single cells sequenced across 50+ species, Single Cell Discoveries delivers high-impact transcriptomic insights with precision and scale. Leveraging state-of-the-art laboratory facilities, advanced sequencing platforms, and tailored bioinformatics support, the company combines high-throughput automation, fast turnaround times, and excellence in single-cell preparation, which are three factors essential for successful and reproducible outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930263922/en/
Contacts
Kaitie Kramer
kkramer@parsebiosciences.com | 858.504.0455
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa and Jason Sudeikis Turn the Simplest Goal in Football Into the Biggest Fan Moments at the FIFA World Cup 2026™18.5.2026 14:00:00 EEST | Press release
At the FIFA World Cup 2026™, everything can change in a split second. A quick pass. A simple finish. A tap in goal. This summer, Visa (NYSE: V), the Worldwide Payment Technology Partner of the FIFA World Cup 2026™, is turning those fleeting moments into something much bigger—launching Tap In, a bold new global campaign based on the belief that everything is a tap in with Visa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518011231/en/ Built around one of football’s most recognizable finishes, Tap In takes the simplest touch in the game and turns it into a powerful metaphor for how Visa works: fast, seamless, and effortless in the moments that matter most. At the FIFA World Cup™, that idea moves beyond storytelling, unlocking opportunity in communities and connecting fans directly to the action as it unfolds live. When Players Tap In, Fans Do Too At the heart of the campaign, Visa brings the passion of football to life a
New Iconic Landmark Danjiang Bridge Opened to Redefine Taiwan18.5.2026 13:02:00 EEST | Press release
The Danjiang Bridge, one of Taiwan’s most significant recent public infrastructure projects, officially opened with a series of large-scale public events, transforming the bridge into a new cultural landmark and civic space. The program featured the “Danjiang Bridge Together Arts Festival,” immersive public activities, and a special performance of Light Chain by Cloud Gate Dance Theatre, symbolizing the integration of architecture, engineering, and the arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260517667930/en/ The Danjiang Bridge is an iconic landmark in Taiwan with global recognition. (Photo via Highway Bureau , Motc) Spanning the mouth of the Tamsui River, the bridge serves as both a major transportation project and a recognizable architectural landmark, establishing a new urban symbol for Taiwan. Designed by Zaha Hadid Architects, the project gained international attention throughout its development and was sel
OdysseyRe Announces New Co-Chief Underwriting Officers for EMEA18.5.2026 10:00:00 EEST | Press release
Odyssey Reinsurance Company (OdysseyRe) today announced the appointments of Tegwen Gromellon and Anne-Claire Serres as co-chief underwriting officers of its EMEA division, effective July 1. They succeed longtime Chief Underwriting Officer, Gaël Le Païh, who is retiring later this year following 36 years with the Company. Based in Paris, Serres joined OdysseyRe in 2018 as the market director for France and will lead the division’s business across France, Africa and the Middle East. Gromellon, who joined OdysseyRe in 2004, has served as market director for Germany, Austria, Benelux and Switzerland since 2019. He will take the lead for the rest of Europe, including the relationship with the Company’s representative office in Stockholm for the Nordic markets and across Turkey. “We are delighted to appoint both Tegwen and Anne-Claire to these important leadership positions,” said Isabelle Dubots-Lafitte, chief executive officer of EMEA for OdysseyRe. “These appointments recognize their sign
Prokarium Reports Positive Interim Data from Phase 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients, Demonstrating Excellent Safety and Encouraging Early Efficacy18.5.2026 10:00:00 EEST | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering bacterial immunotherapies for the treatment of solid tumours, today announced safety and antitumour efficacy results from an interim review of the ongoing Phase 1/1b PARADIGM-1 trial of ZH9 in non-muscle invasive bladder cancer (NMIBC) patients. These data were shared via an oral podium presentation at the American Urology Association (AUA26) Annual Meeting. Prokarium CMO, Dr Josefin-Beate Holz said “These data demonstrate ZH9 as a universally applicable treatment for patients. As the treatment is very well tolerated and is showing impactful outcomes for early and BCG-non-responsive patients alike, it opens up the potential for ZH9 to be a transformative bladder saving treatment.” "There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes," said Ibs Mahmood, CEO of Prokarium. "Pat
Arboris Capital Selects ROYC to Expand Private Markets Capabilities on CapGain Platform18.5.2026 10:00:00 EEST | Press release
Arboris Capital Limited (“Arboris”), a DIFC-based firm arranging alternative investments, authorised by the Dubai Financial Services Authority (DFSA), today announced that it has selected ROYC AB (“ROYC”), a private markets technology and infrastructure provider, to support the continued development of its private markets offering through its platform, CapGain. In its ongoing efforts to expand its private markets capabilities across the Middle East, Arboris has undertaken a strategic review of how to further scale its offering while maintaining the integrity of its existing platform. As a result, Arboris has chosen to integrate ROYC’s fund access, sourcing, and structuring capabilities into CapGain, complementing its existing infrastructure. CapGain is Arboris’s proprietary investment platform, purpose-built to facilitate access between international private market opportunities and Professional Investors in the region. CapGain provides fully digital investor onboarding and KYC, a secu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom